Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xianan Guo
Institutions:
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
Observed institutions:
Second Affiliated Hospital of Zhejiang University,
Zhejiang University
ORCID:
0000-0001-7631-0740
Observed ORCID:
0000-0001-7631-0740
OpenAlex ID:
A5001114105
Predictive Significance of Systemic Immune-Inflammation Index in Patients with Breast Cancer: A Retrospective Cohort Study
2023
·
Yunxiang Zhou
, Xianan Guo
, et al.
·
OncoTargets and Therapy
·
31
PDF
Efficacy, Safety, and Biomarkers of Neoadjuvant Dalpiciclib (CDK4/6 inhibitor) plus Aromatase Inhibitors in Operable HER2‐Negative Luminal B Breast Cancer: A Prospective, Single‐Center, Single‐Arm, Phase II Trial (DANCER)
2025
·
Yunxiang Zhou
, Zhiyun Zhang
, et al.
·
MedComm
·
13
PDF
First‐line CDK4/6 inhibitor‐based combinations for HR+/HER2– advanced breast cancer: A Bayesian network meta‐analysis
2023
·
Xianan Guo
, Yunxiang Zhou
, et al.
·
Journal of Evidence-Based Medicine
·
11
Functional assessment of missense variants of uncertain significance in the cancer susceptibility gene PALB2
2022
·
Shijie Wu
, Lina Qi
, et al.
·
npj Breast Cancer
·
9
PDF
Cyclin-dependent kinase inhibition and its intersection with immunotherapy in breast cancer: more than CDK4/6 inhibition
2022
·
Xianan Guo
, Huihui Chen
, et al.
·
Expert Opinion on Investigational Drugs
·
7
Recent Advances in Antibody-Drug Conjugates and Immunotherapy Combinations for Treatment of Triple-Negative Breast Cancer
2026
·
Huihui Chen
, Wei Lu
, et al.
·
Breast Cancer Targets and Therapy
·
5
PDF
Neoadjuvant Immunotherapy in Triple-Negative Breast Cancer: Striking Potential or Need for Caution?
2025
·
Panni Li
, Xianan Guo
, et al.
·
Aging and Disease
·
5
PDF
Clinical significance of lipid pathway-targeted therapy in breast cancer
2025
·
Dan Li
, Pengcheng Jin
, et al.
·
Frontiers in Pharmacology
·
5
PDF
Revisiting the standard of care for immune checkpoint inhibitors in early-stage triple-negative breast cancer: timing, duration, dose, combination, and patient selection
2026
·
Xi Guo
, Panni Li
, et al.
·
Frontiers in Immunology
·
3
PDF
Management of malignant breast phyllodes tumor with rib invasion during pregnancy: a rare case report and literature review
2026
·
Sijie Yu
, Panni Li
, et al.
·
Frontiers in Oncology
·
1
PDF
Clinical significance of circulating tumor DNA in neoadjuvant-treated HER2-negative luminal B breast cancer.
2024
·
Yunxiang Zhou
, Zhiyun Zhang
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Timing and Patterns of Relapse‐Related Events Following Adjuvant CDK4 /6 Inhibitors Combined With Endocrine Therapy in Patients With HR ‐Positive, HER2 ‐Negative Early Breast Cancer
2026
·
Huihui Chen
, Shijie Wu
, et al.
·
Cancer Medicine
PDF
Real-world outcomes of CDK4/6 inhibitors in combination with endocrine therapy as first-line treatment for HR-positive/HER2-negative advanced breast cancer: multicenter evidence from China
2026
·
Xianan Guo
, Panni Li
, et al.
·
BMC Cancer
Gastric metastasis of invasive lobular breast cancer, misdiagnosed as primary gastric cancer: a case report and literature review
2025
·
Xianan Guo
, Huihui Chen
, et al.
·
Breast Communications
Show more works
View as search
Works count:
15
Citation count:
91
H-index:
5
I10-index:
3
Year
Topic
Type